Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
LONDON - Celadon Pharmaceuticals Plc (AIM:CEL), a UK-based cannabis medicines company, announced Wednesday it plans to delist from London’s AIM market and convert to a private limited company.
The company will seek shareholder approval for the delisting at a general meeting scheduled for July 28, 2025, at The Aston Tavern Hotel in Birmingham. If approved, Celadon’s shares would cease trading on AIM effective August 8, 2025, at 7:00 a.m.
According to a company statement, Celadon’s Chief Executive Officer believes the proposed cancellation is "in the best interests of the Company and its shareholders." The meeting will also include a vote on adopting new articles of association for the company.
Celadon, which focuses on research, cultivation, manufacturing, and sale of cannabis-based medicines, has made the announcement via a circular being distributed to shareholders. The document outlines the background, reasons, and consequences of the proposed delisting, along with the Non-Executive Chair’s views on the matter.
The circular and proposed new articles of association will be available on the company’s website. Shareholders will have the opportunity to vote on these proposals at the general meeting next month.
The announcement was made through a regulatory news service filing dated July 2, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.